Genelux Corporation (GNLX) Fair Value 2026

GNLX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-28, Genelux Corporation (GNLX) trades at $2.66. QOC: 5.5/10. Value Trap Risk: 21/100 (SAFE). 1/13 models active.

Key Facts

Ticker
GNLX
Price
$2.66
Quality Score
5.5/10
Value Trap Risk
21/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give GNLX?

1 Intrinsic Value Models vs. Current Price ($2.66)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · Medium Conviction
 $0.36 -86.4%

All Models Active

All 1 models are displayed above.

What Is Genelux Corporation (GNLX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Genelux Corporation's intrinsic value is estimated at $0.36, suggesting the stock is overvalued at its current price of $2.66. With 1 out of 1 models flagging downside (-86.4% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About GNLX?

1 of 13 models are currently active for GNLX. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does GNLX Rank in Biotechnology?

Among 625 Biotechnology stocks, GNLX ranks #217 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Genelux Corporation operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating GNLX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is GNLX a Value Trap?

CirclFi's Value Trap algorithm assigns GNLX a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Genelux Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Genelux Corporation's fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GNLX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GNLX's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Genelux Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ABVXABIVAX Société AnonymeQOC 5.5SRRKScholar Rock Holding CorporationQOC 5.5LENZLENZ Therapeutics, Inc.QOC 5.5IPHAInnate Pharma S.A.QOC 5.5SPRYARS Pharmaceuticals, Inc.QOC 5.5CNTBConnect Biopharma Holdings LimitedQOC 5.5SNGXSoligenix, Inc.QOC 4.8PDSBPDS Biotechnology CorporationQOC 4.1TNGXTango Therapeutics, Inc.QOC 6.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ABVX · SRRK · LENZ · IPHA · SPRY · CNTB · SNGX · PDSB · TNGX · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to GNLX?

6 companies across all industries closest to GNLX’s Quality of Company score of 5.5/10.

BTOCArmlogi Holding Corp.QOC 5.5USGOU.S. GoldMining Inc.QOC 5.5MYNDMynd.ai, Inc.QOC 5.5XWELXWELL, Inc.QOC 5.5AISPAirship AI Holdings, Inc.QOC 5.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BTOC · USGO · MYND · XWEL · AISP · NVDA

Where Does GNLX Sit in CirclFi's Biotechnology Rankings?

GNLX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Genelux Corporation’s Valuation?

What is Genelux Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Genelux Corporation (GNLX). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GNLX overvalued or undervalued right now?

At $2.66, 0 of 1 active models suggest GNLX may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Genelux Corporation's business model in Biotechnology.

What does a Quality of Company score of 5.5 mean for GNLX?

Genelux Corporation's QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on GNLX?

CirclFi analyzes GNLX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is GNLX a value trap in 2026?

Genelux Corporation's Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Genelux Corporation (GNLX) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/GNLX/ · Methodology
Primary sources for this GNLX valuation
  • Financial statements: Genelux Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001231457) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for GNLX as of ; valuations recomputed .